Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The transcription factor RUNX-1 plays a key role in megakaryocyte differentiation and is mutated in cases of myelodysplastic syndrome and leukemia.”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
In the citing paper
“Germ line mutations in RUNX-1 cause familial platelet disorder with the propensity to develop acute myelogenous leukemia (FPD/AML), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet defects and a high incidence of developing myelodysplastic syndrome (MDS) and leukemia”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
Citations
Cites
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355 · cited 1×
“Fusion of PDGF Receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.”
BackgroundWang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Self-citationGolub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationOncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis.
Weinberg, R. A. (1989) · PubMed · Cited by 949
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732 · cited 1×
“; the CBFB / MYH11 fusion associated with inv(16) myelomonocytic leukaemia with eosinophili”
BackgroundFusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
Self-citationShivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., & Orkin, S. H. (1995) · Cell · doi:10.1016/0092-8674(95)90531-6 · Cited by 693 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
BackgroundShivdasani, R. A., Fujiwara, Y., McDevitt, M. A., & Orkin, S. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3965 · Cited by 674 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
Background
Cited by
Items 301–400 of 1,000
T-lymphoid, megakaryocyte, and granulocyte development are sensitive to decreases in CBFβ dosage.
Talebian, L., Li, Z., Guo, Y., Gaudet, J., Speck, M. E., Sugiyama, D., Kaur, P., Pear, W. S., Maillard, I., & Speck, N. A. (2007) · Blood · doi:10.1182/blood-2006-05-021188 · Cited by 70
Self-citationRUNX family: Oncogenes or tumor suppressors (Review)
Otálora-Otálora, B. A., Henr�quez, B., Kleine, L. L., & Rojas, A. P. (2019) · Oncology Reports · doi:10.3892/or.2019.7149 · Cited by 83
“If RUNX1 chimeric genes inactivate the function of RUNX1 to cause leukemia, then functional loss by mutations must also cause acute myeloid leukemia; in fact, patients with different types of leukemia possess heterozygous or homozygous sporadic and familial mutations (120,121).”
BackgroundCardoso, S. R., Ryan, G., Walne, A. J., Ellison, A., Lowe, R., Tummala, H., Rio‐Machín, A., Collopy, L. C., Seraihi, A. A., Wallis, Y., et al. (2016) · Leukemia · doi:10.1038/leu.2016.124 · Cited by 70
Core binding factor and its role in normal hematopoietic development
Speck, N. A. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200107000-00002 · Cited by 72
Self-citationBiased exon/intron distribution of cryptic and de novo 3' splice sites
Královičová, J., Christensen, M. B., & Vořechovský, I. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki811 · Cited by 75
Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69
Mll5 contributes to hematopoietic stem cell fitness and homeostasis
Zhang, Y., Wong, J., Klinger, M., Tran, M. T., Shannon, K. M., & Killeen, N. (2009) · Blood · doi:10.1182/blood-2008-05-159905 · Cited by 68
Tsai, S., Shih, L., Liang, S., Huang, Y., Kuo, M., Huang, C., Shih, Y., Lin, T., Chiu, M.-C., & Liang, D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2203 · Cited by 72
“Familial platelet disorder (FPD) is an autosomal dominant disorder caused by germline heterozygous–inherited mutation of RUNX1 gene (30).”
BackgroundProviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.
Wotton, S., Stewart, M. A., Blyth, K., Vaillant, F., Kilbey, A., Neil, J. C., & Cameron, E. R. (2002) · PubMed · Cited by 85
Rubnitz, J. E., Gibson, B. E. S., & Smith, F. O. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.11.003 · Cited by 69
Huang, H., Woo, A. J., Waldon, Z., Schindler, Y., Moran, T. B., Zhu, H. H., Feng, G.-S., Steen, H., & Cantor, A. B. (2012) · Genes & Development · doi:10.1101/gad.192054.112 · Cited by 70
“…mutations leading to RUNX1 haploinsufficiency cause familial platelet disorder with propensity to develop AML (FPD/AML), an autosomal dominant syndrome characterized by thrombocytopenia, platelet dysfunction, and an ;35% lifetime risk of developing MDS/AML (Song et al. 1999; Owen et al. 2008).”
BackgroundIdentification of RUNX1/AML1 as a classical tumor suppressor gene
Silva, F. P. G., Morolli, B., Storlazzi, C. T., Anelli, L., Wessels, H. M. C., Bezrookove, V., Kluin‐Nelemans, H. C., & Giphart-Gassler, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206141 · Cited by 74
“Polymorphic markers within RUNX1 are described elsewhere (Song et al., 1999).”
BackgroundInfluentialMolecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations
Harada, Y., & Harada, H. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21769 · Cited by 94
“…germline mutation of the AML1/ RUNX1 gene is also known to be causative for familial platelet disorder with predisposition to AML (FPD/AML) (Song et al., 1999; Buijs et al., 2001; Michaud et al., 2002; Walker et al., 2002; Sun et al., 2004; Heller et al., 2005; Kirito et al., 2008), an…”
BackgroundErythroid and megakaryocytic transformation
Wickrema, A., & Crispino, J. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210763 · Cited by 80
Normal and transforming functions of RUNX1: A perspective
Mikhail, F. M., Sinha, K. K., Saunthararajah, Y., & Nucifora, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20538 · Cited by 81
“Analysis of FPD/AML BM cells showed a decrease in megakaryocyte colony formation, linking RUNX1 dosage to megakaryopoiesis (Song et al., 1999).”
BackgroundInfluentialTang, Y.-Y., Shi, J., Zhang, L., Davis, A., Bravo, J., Warren, A. J., Speck, N. A., & Bushweller, J. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007350200 · Cited by 68
Self-citationMulloy, J. C., Jankovic, V. S., Wunderlich, M., Delwel, R., Cammenga, J., Krejci, O., Zhao, H., Valk, P. J. M., Löwenberg, B., & Nimer, S. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404701102 · Cited by 74
Preleukemia: one name, many meanings
Koeffler, H. P., & Leong, G. X. Y. (2016) · Leukemia · doi:10.1038/leu.2016.364 · Cited by 74
Haploinsufficient tumor suppressor genes.
Inoue, K., & Fry, E. A. (2017) · PubMed · Cited by 85
Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26
Homan, C. C., Scott, H. S., & Brown, A. L. (2023) · Blood · doi:10.1182/blood.2022017735 · Cited by 69
P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1
Gilles, L., Guièze, R., Bluteau, D., Cordette-Lagarde, V., Lacout, C., Favier, R., Larbret, F., Debili, N., Vainchenker, W., & Raslová, H. (2008) · Blood · doi:10.1182/blood-2007-09-113266 · Cited by 72
Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy
Solh, M., Yohe, S. L., Weisdorf, D. J., & Üstün, C. (2014) · American Journal of Hematology · doi:10.1002/ajh.23821 · Cited by 75
“platelet disorder with propensity to AML (FPD/AML) [28]; the minimally differentiated subtype of AML (AML M0) [29,30]; gene overexpression in pediatric ALL (frequency 1.”
BackgroundGenetic predisposition to leukemia and other hematologic malignancies
Feurstein, S. K., Drazer, M. W., & Godley, L. A. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.003 · Cited by 68
“The first genes involved in inherited MDS/AL, RUNX1 and CEBPA, were identified a decade ago [2,3], but the number of genes involved in inherited MDS/AL has grown dramatically in recent years with the advent of more affordable next-generation sequencing (NGS).”
BackgroundDrachman, J. G., Jarvik, G. P., & Mehaffey, M. G. (2000) · Blood · doi:10.1182/blood.v96.1.118 · Cited by 66
Lezon-Geyda, K., Najfeld, V., & Johnson, E. (2001) · Leukemia · doi:10.1038/sj.leu.2402108 · Cited by 66
Kundu, M., Chen, A., Anderson, S., Kirby, M., Xu, L., Castilla, L. H., Bodine, D., & Liu, P. P. (2002) · Blood · doi:10.1182/blood-2002-04-1064 · Cited by 68
“(D) Western blot analysis using a monoclonal antibody against Cbf (1-141) demonstrated expression of endogenous Cbf (22 kDa) or the Cbf fusion proteins in 3 ES cell lines.”
MethodRole of AML1/Runx1 in the pathogenesis of hematological malignancies
Kurokawa, M., & Hirai, H. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01364.x · Cited by 73
Glembotsky, A. C., Bluteau, D., Espasandin, Y. R., Goette, N. P., Marta, R. F., Oyarzún, C. P. M., Korin, L., Lev, P. R., Laguens, R. P., Molinas, F. C., et al. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12550 · Cited by 69
Bluteau, D., Gilles, L., Hilpert, M., Antony‐Debré, I., James, C., Debili, N., Camara‐Clayette, V., Wagner‐Ballon, O., Cordette-Lagarde, V., Robert, T., et al. (2011) · Blood · doi:10.1182/blood-2010-12-325555 · Cited by 64
“Analysis of 32 FPD/AML (OMIM 601399) pedigrees has identified various germ line heterozygous alterations in RUNX1 gene.(1,3-16) Missense and nonsense mutations in the conserved Nterminus Runt homology domain (RHD) generate RUNX1 proteins with impaired DNA binding that behave as dominant negative (DN) mutants whereas l…”
BackgroundRUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Zhou, N., Gutierrez-Uzquiza, A., Zheng, X. Y., Chang, R., Vogl, D. T., Garfall, A. L., Bernabei, L., Saraf, A., Florens, L., Washburn, M. P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0403-2 · Cited by 61
Self-citationChromosome 21 abnormalities with AML1 amplification in acute lymphoblastic leukemia
Coniat, M. L., Nguyen‐Khac, F., Daniel, M., Bernard, O., & Berger, R. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1188 · Cited by 64
“Since point mutations in the AML1 gene runt domain have been reported in myeloid disorders (Osato et al., 1999; Song et al., 1999; Preudhomme et al., 2000), point mutations were searched for in ALL patients with extra copies of AML1.”
BackgroundLook, A. T. (2005) · Hematology · doi:10.1182/asheducation-2005.1.156 · Cited by 73
Histone arginine methylation keeps RUNX1 target genes in an intermediate state
Herglotz, J., Kuvardina, O. N., Kolodziej, S., Kumar, A., Hussong, H., Grez, M., & Lausen, J. (2012) · Oncogene · doi:10.1038/onc.2012.274 · Cited by 66
Nakagawa, M. M., Shimabe, M., Watanabe‐Okochi, N., Arai, S., Yoshimi, A., Shinohara, A., Nishimoto, N., Kataoka, K., Sato, T., Kumano, K., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326710 · Cited by 69
RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes
Koh, C. P., Wang, C. Q., Ng, C. E. L., Ito, Y., Araki, M., Tergaonkar, V., Huang, G., & Osato, M. (2013) · Leukemia · doi:10.1038/leu.2013.200 · Cited by 65
Chong, C.-E., Venugopal, P., Stokes, P. H., Lee, Y. K., Brautigan, P. J., Yeung, D. T. O., Babic, M., Engler, G. A., Lane, S., Klingler‐Hoffmann, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.196 · Cited by 65
Molecular insights into Down syndrome-associated leukemia
Vyas, P., & Crispino, J. D. (2007) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328013e7b2 · Cited by 65
The p53-MDM2 network: from oscillations to apoptosis
Bose, I., & Ghosh, B. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0103-3 · Cited by 62
“The gene dosage effect is called haploinsuffi ciency (HI) and has been verifi ed experimentally (Venkatachalam et al 1998; Song et al 1999).”
BackgroundWalker, L. C., Stevens, J., Campbell, H., Corbett, R., Spearing, R., Heaton, D., Macdonald, D. H., Morris, C. M., & Ganly, P. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03512.x · Cited by 61
“Mutations were clustered across the Runt domain in six FPD/AML pedigrees and were predicted to influence conformation of the final gene product in affected individuals (Song et al, 1999).”
BackgroundMethodInfluentialLey, T. J., Minx, P. J., Walter, M. J., Ries, R. E., Sun, H., McLellan, M., DiPersio, J. F., Link, D. C., Tomasson, M. H., Graubert, T. A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2335924100 · Cited by 61
The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO
Peterson, L. F., Yan, M., & Zhang, D.-E. (2007) · Blood · doi:10.1182/blood-2006-03-012575 · Cited by 61
Guéguen, P., Rouault, K., Chen, J., Raguénès, O., Fichou, Y., Hardy, E., Gobin, E., Pan‐Petesch, B., Kerbiriou, M., Trouvé, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074728 · Cited by 66
“MYH9 (MIM 160775) is the most frequently affected gene [2,3], followed by other less common ones, such as FLNA [4] (MIM 606672), FLI1 [5] (MIM 193067), TUBB1 [6] (MIM 612901), CBFA2 [7] (MIM 151385), ITGA2B [8] (MIM 607759), ITGB3 [9] (MIM 173470), ANKRD26 [10] (MIM 313900) and CYCS [11] (MIM 612004).”
Wotton, S., Terry, A., Kilbey, A., Jenkins, A., Herzyk, P., Cameron, E. R., & Neil, J. C. (2008) · Oncogene · doi:10.1038/onc.2008.195 · Cited by 60
“The tumour-suppressive potential of this family has been demonstrated most clearly for RUNX1, where haploinsufficiency leads to familial platelet disorder, a rare syndrome that entails predisposition to myeloid leukaemia (Song et al., 1999), and somatic loss of function mutations are observed affecting one or both all…”
BackgroundManagement of Chronic Childhood Immune Thrombocytopenic Purpura: AIEOP Consensus Guidelines
Mattia, D. D., Vecchio, G. C. D., Russo, G. M., Santis, A. D., Ramenghi, U., Notarangelo, L. D., Jankovic, M., Molinari, A. C., Zecca, M., Nobili, B., et al. (2009) · Acta Haematologica · doi:10.1159/000268855 · Cited by 60
“Clinically, the chronic ITP patient may show a cyclic course, but could be refractory or dependent on pharmacological treatment, too; in some cases, the cause of ITP becomes evident. Therefore, it is appropriate to periodically reconsider (every 6–12 months) various etiological hypotheses in relation to the patient’s…”
BackgroundInfluentialSteensma, D. P., Gibbons, R. J., Mesa, R. A., Tefferi, A., & Higgs, D. R. (2005) · European Journal of Haematology · doi:10.1111/j.1600-0609.2004.00363.x · Cited by 58
Transcription factor mutations as a cause of familial myeloid neoplasms
Churpek, J. E., & Bresnick, E. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120854 · Cited by 63
Alterations of the AML1 transcription factor in human leukemia
Downing, J. R., Higuchi, M., Lenny, N. T., & Yeoh, A. E. J. (2000) · Seminars in Cell and Developmental Biology · doi:10.1006/scdb.2000.0183 · Cited by 64
Familial (inherited) leukemia, lymphoma, and myeloma: an overview
Segel, G. B., & Lichtman, M. A. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2003.10.005 · Cited by 60
Bäckström, S., Wolf‐Watz, M., Grundström, C., Härd, T., Grundström, T., & Sauer, U. H. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00702-7 · Cited by 60
The Runx genes as dominant oncogenes
Cameron, E. R., Blyth, K., Hanlon, L., Kilbey, A., Mackay, N. A., Stewart, M. A., Terry, A., Vaillant, F., Wotton, S., & Neil, J. C. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00031-7 · Cited by 60
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy
Gill, H., Leung, A. Y. H., & Kwong, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040440 · Cited by 62
Hake, C. R., Graubert, T. A., & Fenske, T. S. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705547 · Cited by 61
RUNX transcription factors: association with pediatric asthma and modulated by maternal smoking
Haley, K. J., Lasky-Su, J., Manoli, S. E., Smith, L. A., Shahsafaei, A., Weiss, S. T., & Tantisira, K. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00348.2010 · Cited by 58
“Additionally, they can act as both oncogenes and tumor suppressors (9, 34, 38, 41, 45, 62).”
BackgroundRUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53
Wotton, S., Blyth, K., Kilbey, A., Jenkins, A., Terry, A., Bernardin, F., Friedman, A. D., Baxter, E. W., Neil, J. C., & Cameron, E. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207729 · Cited by 64
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations
Ozaki, T., Yu, M., Yin, D., Sun, D., Zhu, Y., Bu, Y., & Sang, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4217-9 · Cited by 64
“In contrast to the other RUNX family members such as RUNX1 and RUNX3 whose mutations are tightly linked to the promotion of leukemia and gastric cancer, respectively [116, 117], the initial stud-”
BackgroundInherited thrombocytopenias: toward a molecular understanding of disorders of platelet production
Geddis, A. E., & Kaushansky, K. (2004) · Current Opinion in Pediatrics · doi:10.1097/00008480-200402000-00005 · Cited by 62
Elagib, K. E., & Goldfarb, A. N. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.010 · Cited by 66
Ågerstam, H., Lilljebjörn, H., Lassen, C., Swedin, A., Richter, J., Vandenberghe, P., Johansson, B., & Fioretos, T. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20442 · Cited by 59
“Furthermore, the autosomal dominant familial platelet disorder with predisposition to AML (FPD/AML) has been linked to haploinsufficiency of RUNX1 (Song et al., 1999; Michaud et al., 2002).”
BackgroundNishimura, M., Fukushima‐Nakase, Y., Fujita, Y., Nakao, M., Toda, S., Kitamura, N., Abe, T., & Okuda, T. (2003) · Blood · doi:10.1182/blood-2003-06-2109 · Cited by 59
Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7
Langabeer, S. E., Gale, R. E., Rollinson, S. J., Morgan, G. J., & Linch, D. C. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10031 · Cited by 57
“For each patient, fragments encompassing exons 3, 4, and 5 were amplified using intronic polymerase chain reaction (PCR) primers previously published by Song et al. (1999).”
BackgroundMethodInfluentialOsman, D., Gobert, V., Ponthan, F., Heidenreich, O. T., Haenlin, M., & Waltzer, L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902449106 · Cited by 60
“In mammals, AML1 haplo-insufficiency causes blood cell progenitor expansion (33, 34) and the growthpromoting activity of AML1-ETO was attributed to inhibition of AML1 activity as well as to additional gain of function mechanisms (7).”
BackgroundMatsuno, N., Osato, M., Yamashita, N., Yanagida, M., Nanri, T., Fukushima, T., Motoji, T., KUSUMOTO, S., Towatari, M., Suzuki, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403160 · Cited by 60
Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium
Lie‐A‐Ling, M., Marinopoulou, E., Lilly, A. J., Challinor, M., Patel, R., Lancrin, C., Kouskoff, V., & Lacaud, G. (2018) · Development · doi:10.1242/dev.149419 · Cited by 61
“Within the context of the definitive adult blood system, alterations in RUNX1 dosage or activity have been associated with several blood-related disorders with both reduction (thrombocytopenia, myelodysplastic syndrome) and gain (Down syndrome hematopoietic disorders) of functional Runx1 alleles leading to abnormaliti…”
BackgroundAcute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells
Wesely, J., Kotini, A. G., Izzo, F., Luo, H., Yuan, H., Sun, J., Georgomanoli, M., Zviran, A., Deslauriers, A. G., Dusaj, N. N., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107688 · Cited by 57
Transcriptional control of megakaryocyte development
Goldfarb, A. N. (2007) · Oncogene · doi:10.1038/sj.onc.1210762 · Cited by 65
“Marrow megakaryocytic morphology has varied from reportedly normal (Song et al., 1999) to abnormal with immature-appearing megakaryocytes that are increased in number (Walker et al.”
BackgroundXu, G., Kanezaki, R., Toki, T., Watanabe, S., Takahashi, Y., Terui, K., Kitabayashi, I., & Ito, E. (2006) · Leukemia · doi:10.1038/sj.leu.2404223 · Cited by 65
Fukuyama, T., Sueoka, E., Sugio, Y., Otsuka, T., Niho, Y., Akagi, K., & Kozu, T. (2001) · Oncogene · doi:10.1038/sj.onc.1204794 · Cited by 59
“Recent reports suggest that point mutations in AML1, which will introduce loss of function, are also observed in a particular subset of AML (Osato et al., 1999; Song et al., 1999).”
BackgroundLou, J., Cao, W., Bernardin, F., Ayyanathan, K., Rauscher, F. J., & Friedman, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1203588 · Cited by 60
“…or t(8;21) carry mutations which result in the expression of AML1 variants defective for DNA-binding or lacking its C-terminal trans-activation domains and by the ®nding of CBFA2 haploinsu ciency in familial platelet disorder with predisposition to AML (Osato et al., 1999; Song et al., 1999).”
BackgroundCBFβ is critical for AML1-ETO and TEL-AML1 activity
Roudaia, L., Cheney, M. D., Manuylova, E., Chen, W., Morrow, M., Park, S., Lee, C.-T., Kaur, P., Williams, O., Bushweller, J. H., et al. (2009) · Blood · doi:10.1182/blood-2008-03-147207 · Cited by 59
Self-citationHoman, C. C., King‐Smith, S. L., Lawrence, D., Arts, P., Feng, J., Andrews, J., Armstrong, M., Ha, T., Dobbins, J., Drazer, M. W., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278762 · Cited by 55
“Pre-leukemic: Median (range), years 34 (1-76)”
BackgroundVegesna, V., Takeuchi, S., Hofmann, W.-K., Ikezoe, T., Tavor, S., Krug, U., Fermin, A. C., Heaney, A., Miller, C. W., & Koeffler, H. P. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00150-3 · Cited by 54
Natural history study of patients with familial platelet disorder with associated myeloid malignancy
Cunningham, L., Merguerian, M., Calvo, K. R., Davis, J., Deuitch, N. T., Dulau‐Florea, A., Patel, N., Yu, K., Sacco, K. A., Bhattacharya, S., et al. (2023) · Blood · doi:10.1182/blood.2023019746 · Cited by 54
Aneja, K. K., Jalagadugula, G. S., Mao, G., Singh, A., & Rao, A. K. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04154.x · Cited by 57
“RUNX1 mutations are associated with familial, autosomal dominant thrombocytopenia, platelet dysfunction, and predisposition to acute leukemia [19,25].”
BackgroundCompound haploinsufficiencies of Ebf1 and Runx1 genes impede B cell lineage progression
Lukin, K., Fields, S., Lopez, D., Cherrier, M., Ternyak, K., Ramírez, J., Feeney, A. J., & Hagman, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003525107 · Cited by 52
Wang, W., Schwemmers, S., Hexner, E. O., & Pahl, H. L. (2010) · Blood · doi:10.1182/blood-2009-11-254664 · Cited by 63
Bartfeld, D., Shimon, L. J. W., Couture, G. C., Rabinovich, D., Frolow, F., Levanon, D., Groner, Y., & Shakked, Z. (2002) · Structure · doi:10.1016/s0969-2126(02)00853-5 · Cited by 54
AML1/RUNX1 Works as a Negative Regulator of c-Mpl in Hematopoietic Stem Cells
Satoh, Y., Matsumura, I., Tanaka, H., Ezoe, S., Fukushima, K., Tokunaga, M., Yasumi, M., Shibayama, H., Mizuki, M., Era, T., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804768200 · Cited by 63
Langerhans cell histiocytosis: A pathologic combination of oncogenesis and immune dysregulation
Egeler, R. M., Annels, N. E., & Hogendoorn, P. C. W. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.10464 · Cited by 54
Weber, B. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00026-0 · Cited by 81
Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylation
Hamelin, V., Letourneux, C., Roméo, P., Porteu, F., & Gaudry, M. (2005) · Blood · doi:10.1182/blood-2005-07-2953 · Cited by 56
Zhang, C., Thornton, M. A., Kowalska, M. A., Sachis, B. S., Feldman, M. D., Poncz, M., McKenzie, S. E., & Reilly, M. P. (2001) · Blood · doi:10.1182/blood.v98.3.610 · Cited by 53
Self-citationChao, M. M., Todd, M. A. M., Kontny, U., Neas, K. R., Sullivan, M. J., Hunter, A. G. W., Picketts, D. J., & Kratz, C. P. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22574 · Cited by 53
“Moreover, constitutional mutations have been uncovered in several leukemia-associated transcription factors such as RUNX1 [4] (familial thrombocytopenia with propensity to AML) and GATA1 (congenital dyserythropoietic anemia with macrothrombocytopenia) [5].”
BackgroundSelf-citationTang, Y.-Y., Crute, B. E., Kelley, J. J., Huang, X., Yan, J., Shi, J., Hartman, K. L., Laue, T. M., Speck, N. A., & Bushweller, J. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01312-0 · Cited by 50
Self-citationIzumi, K., Brooks, S. S., Feret, H. A., & Zackai, E. H. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35368 · Cited by 54
Runx1 promotes B-cell survival and lymphoma development
Blyth, K., Slater, N., Hanlon, L., Bell, M., Mackay, N. A., Stewart, M. A., Neil, J. C., & Cameron, E. R. (2009) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2009.01.013 · Cited by 54
Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia
Li, R., Sobreira, N., Witmer, P. D., Pratz, K. W., & Braunstein, E. M. (2016) · Haematologica · doi:10.3324/haematol.2015.139790 · Cited by 52
I NHERITED D EFECTS OF P LATELET F UNCTION
Nurden, A. T., & Nurden, P. (2001) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2001.00052.x · Cited by 56
Honda, H., Nagamachi, A., & Inaba, T. (2014) · Oncogene · doi:10.1038/onc.2014.196 · Cited by 52
Iizuka, H., Kagoya, Y., Kataoka, K., Yoshimi, A., Miyauchi, M., Taoka, K., Kumano, K., Yamamoto, T., Hotta, A., Arai, S., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.004 · Cited by 53
Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation
Socié, G., Baker, K. S., & Bhatia, R. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.005 · Cited by 51
Curtiss, N. P., Bonifas, J. M., Lauchle, J., Balkman, J. D., Kratz, C. P., Emerling, B. M., Green, E. D., Beau, M. M. L., & Shannon, K. (2005) · Genomics · doi:10.1016/j.ygeno.2005.01.013 · Cited by 51
GATA Transcription Factors in Hematologic Disease
Cantor, A. B. (2005) · International Journal of Hematology · doi:10.1532/ijh97.04180 · Cited by 55
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy
Ge, Y., LaFiura, K. M., Dombkowski, A. A., Chen, Q., Payton, S. G., Buck, S. A., Salagrama, S., Diakiw, A. E., Matherly, L. H., & Taub, J. W. (2007) · Leukemia · doi:10.1038/sj.leu.2405066 · Cited by 54
Taketani, T., Taki, T., Takita, J., Tsuchida, M., Hanada, R., Hongo, T., Kaneko, T., Manabe, A., Ida, K., & Hayashi, Y. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10246 · Cited by 63
“AML1 germline mutations were also found in FPD/AML (Song et al., 1999; Buijs et al., 2001).”
BackgroundResultPeterson, L. F., Boyapati, A., Ranganathan, V., Iwama, A., Tenen, D. G., Tsai, S., & Zhang, D.-E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10205-10219.2005 · Cited by 51
“Two AML1 C-terminal deletion constructs—AML1(1-289) and AML1(1213)—were used in this study.”
BackgroundMethodInfluentialRelationship of Chromosome 21 and Acute Leukemia in Children With Down Syndrome
Taub, J. W. (2001) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200103000-00012 · Cited by 51
“Several chromosome 21-localized genes may be linked to leukemogenesis in DS, including the genes encoding for the interferon , ß, and receptors and the transcription factor oncogenes ETS2, ERG, and AML1 (21).”
BackgroundA RUNX trio with a taste for autoimmunity
Alarcón-Riquelme, M. E. (2003) · Nature Genetics · doi:10.1038/ng1203-299 · Cited by 51
Molecular Mechanisms of Myelodysplastic Syndrome
Hirai, H. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg037 · Cited by 62
“Heterozygous missense mutation of the AML1 gene is noted to be causative for familial platelet disorder (FPD) with predisposition to AML, in which haploinsufficiency of AML1 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia (61).”
BackgroundNoh, J.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179615 · Cited by 54
“For instance, GATA1 mutations could affect both megakaryopoiesis and erythropoiesis [71], whereas variants of RUNX1 and ETV6 are involved in leukemia predisposition [72,73].”
BackgroundShiba, N., Hasegawa, D., Park, H., Murata, C., Sato‐Otsubo, A., Ogawa, C., Manabe, A., Arakawa, H., Ogawa, S., & Hayashi, Y. (2011) · Blood · doi:10.1182/blood-2011-02-333435 · Cited by 52
Metadata
- Authors
- Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D.-C., Busque, L., Kurnit, D., Willman, C., Gewirtz, A. M., Speck, N. A., Bushweller, J. H., Li, F. P., Gardiner, K., Poncz, M., Maris, J. M., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Brown University (US)
- University of Pennsylvania (US)
- Leicester Royal Infirmary (GB)
- St Vincent Hospital (US)
- Hôpital Maisonneuve-Rosemont (CA)
- University of Michigan (US)
- University of New Mexico (US)
- Dartmouth College (US)
- University of Virginia (US)
- Harvard University (US)
- Roosevelt Institute (US)
- Corresponding author
- Gilliland, D. Gary
- ORCID
- Venue
- Nature Genetics
- Published
- 1999-10
- Volume
- 23
- Issue
- 2
- Pages
- 166-175
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1739103212
- Cited by
- 1,100
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 27 · 2023: 32 · 2022: 29 · 2021: 36 · 2020: 46 · 2019: 33 · 2018: 26 · 2017: 61 · 2016: 54 · 2015: 35 · 2014: 30 · 2013: 33 · 2012: 53
- FWCI
- 25.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ai039536-04)
- National Cancer Institute (R01CA081932, R01-CA78545, R01 CA81932, R01CA078545)
- National Institute of Allergy and Infectious Diseases (R29 AI39536)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- RUNX1, haploinsufficiency, autosomal dominant inheritance, missense mutations, megakaryopoiesis, megakaryocyte colony formation, platelet disorders, chromosome 21q, nonsense mutation, intragenic deletion
- MeSH terms
- Amino Acid Sequence, Base Sequence, Blood Platelets, Chromosome Mapping, Colony-Forming Units Assay, DNA Mutational Analysis, DNA-Binding Proteins, Family Health, Female, Genotype, Hematopoiesis, Heterozygote, Humans, Male, Megakaryocytes, Molecular Sequence Data, Mutation, Pedigree, Proto-Oncogene Proteins, RNA, Sequence Homology, Nucleic Acid, Thrombocytopenia, Transcription Factors, Leukemia, Myeloid, Acute, Sequence Deletion, Sequence Homology, Amino Acid, In Situ Hybridization, Fluorescence, Microsatellite Repeats, Genetic Predisposition to Disease, Reverse Transcriptase Polymerase Chain Reaction, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.